Vectara Launches Factual Consistency Score Powered by Upgraded Hughes Hallucination Evaluation Model to Enhance Transparency in GenAI Responses
Vectara, the trusted Generative AI product platform, announced the inclusion of a Factual Consistency Score (FCS) for all generative responses based on an evolved version of the groundbreaking Hughes Hallucination Evaluation Model (HHEM)—the #1 hallucination detection model on Hugging Face with 100,000+ downloads since its launch last November. The associated Hallucination Leaderboard is now the industry standard for how LLMs benchmark their average factual consistency. Vectara’s end-to-end Retrieval Augmented Generation-as-a-service (RAGaaS) platform is setting a new standard as an industry-first feature for GenAI response transparency by providing real-time end-to-end RAG observability. This innovative metric provides unprecedented visibility into the factual consistency of summarized responses within Vectara’s RAGaaS platform, empowering users to set personalized thresholds for response acceptance based on a detailed accuracy score.
With average hallucination rates of LLMs on the market ranging from 3% to 16.2%, the risk of unknown inaccuracies in their response remains a major concern, preventing widespread business adoption of this powerful technology. Vectara mitigates this ambiguity for enterprises by providing a Factual Consistency Score grading the likelihood that the generated response is a hallucination or not. Only with a standardized, scientifically calculated method for grading responses can businesses responsibly introduce GenAI into business critical applications. Users have the ability to set thresholds for response acceptance based on a detailed accuracy score, giving product teams the flexibility to act on this information according to their preferences.
Vectara’s Factual Consistency Score is a groundbreaking tool in GenAI, setting a new benchmark for real-time hallucination detection and offering superior performance, affordability, and speed, thus marking a significant leap forward in trust. Its efficiency and effectiveness enable businesses to deploy GenAI into critical product use cases without being worried about exposure to liabilities that might arise from hallucinated responses.
Vectara's Factual Consistency Score equips developers with the capability to refine and enhance a wide range of applications, from internal Q&A systems to the quality of interactions with end consumers. The strength of this score lies in its calibration, making it interpretable as a direct probability—for instance, a score of 0.98 indicates a 98% probability of factual consistency. This contrasts sharply with many contemporary ML classifiers that disregard calibration, thus sacrificing clarity and direct interpretability.
"Integrating Vectara's Factual Consistency Score into the Yobi app will revolutionize how we handle AI transparency and accuracy for business use cases. By providing visibility and accountability into answers provided by our platform, we can stay true to our commitment to responsible AI that enterprises can depend on,” said Ahmed Reza, Founder and CEO of the Yobi app. “As a Co-Innovate Partner with Vectara, we're thrilled to see such advanced technology directly incorporated into the Vectara platform.”
The advanced HHEM that powers the Factual Consistency Score gives greater visibility than previously released open-sourced versions, offering enhanced accuracy and extended language support. This initiative is part of Vectara's commitment to transparency and control, empowering businesses with the autonomy to manage AI responses effectively.
"Just as we were early in pioneering RAG to enhance the relevance and quality of generated content, we are once again at the forefront of responsible AI by being completely open about our efforts to mitigate hallucinations in Generative AI," said Amr Awadallah, co-founder and CEO of Vectara. "By providing our customers with real-time access to factual consistency scores, we're not just engineering trust; we're handing over the control, enabling them to make informed decisions on how to utilize the responses generated by our RAGaaS platform."
About Vectara
Vectara is an end-to-end platform for embedding powerful generative AI features into applications with extraordinary results. As an end-to-end Retrieval Augmented Generation (RAG) platform, Vectara delivers the shortest path to a correct answer/action through a safe, secure, and trusted entry point. Vectara never trains on your data, allowing businesses to embed generative AI capabilities without the risk of data or privacy violations. To learn more, visit vectara.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326712242/en/
Contact information
Carly Bourne
carly@bulleitgroup.com
423-443-0449
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
